Recombinant annexin A5 (Annexin Pharmaceuticals)

重组膜联蛋白A5 (Annexin Pharmaceuticals)

Report date: 2024/02/05 20:04:22

Base Information

Drug NameRecombinant annexin A5 (Annexin Pharmaceuticals)
Drug Alias NameANXVANXV (Annexin A5)ANXV (Human Recombinant Annexin A5)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionPhosphatidylserine modulatorsPhospholipases A2 inhibitorsUrokinase plasminogen activator stimulants
TargetsPhosphatidylserinePhospholipases A2Urokinase plasminogen activator
Therapy Area/IndicationsAnemia, Sickle CellCardiovascular DiseasesRetinal Vein Occlusion +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnnexin Pharmaceuticals AB
China Registration ClassN/A

Develop Information

Active CompaniesAnnexin Pharmaceuticals AB
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle CellCardiovascular DiseasesRetinal Vein Occlusion +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A